



CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783
crobb@corcept.com
www.corcept.com

**CORCEPT THERAPEUTICS TO ANNOUNCE FOURTH QUARTER AND FULL-YEAR
2017 FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE, HOST CONFERENCE CALL**

MENLO PARK, Calif., (February 15, 2018) – Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its 2017 financial results and provide a corporate update on February 22, 2018. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Conference Call Information

To participate, dial 1-800-289-0459 from the United States or 1-323-794-2558 internationally approximately 10 minutes before the start of the call. The passcode is 094798.

A replay will be available through March 8, 2018 at 1-888-203-1112 from the United States and 1-719-457-0820 internationally. The passcode will be 1581123.

About Corcept Therapeutics Incorporated

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym is the company's first FDA-approved medication. Corcept has a large portfolio of proprietary compounds that selectively modulate the effects of cortisol but not progesterone. Corcept owns extensive United States and foreign intellectual property covering the use of cortisol modulators in the treatment of a wide variety of serious disorders, including Cushing's syndrome. It also holds composition of matter patents covering its selective cortisol modulators.